Posted by Michael Wonder on 18 Feb 2025
Welireg (belzutifan) receives first European Commission approval for two indications
18 February 2025 - Welireg is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
Merck today announced that the European Commission has conditionally approved Welireg (belzutifan), Merck’s oral hypoxia-inducible factor-2 alpha inhibitor, as monotherapy for two indications.
